Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -274.45M | -325.66M | -331.40M | -334.52M | -342.99M |
| Total Depreciation and Amortization | 11.54M | 14.17M | 16.28M | 18.05M | 19.63M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.78M | 157.01M | 152.99M | 150.80M | 164.09M |
| Change in Net Operating Assets | -9.89M | -10.53M | -9.36M | -9.44M | -3.12M |
| Cash from Operations | -150.02M | -165.02M | -171.48M | -175.12M | -162.39M |
| Capital Expenditure | -780.00K | -520.00K | -517.00K | -680.00K | -464.00K |
| Sale of Property, Plant, and Equipment | 287.00K | 263.00K | -- | -- | -- |
| Cash Acquisitions | -41.20M | -31.35M | -31.35M | -31.35M | -31.35M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.79M | 170.57M | 169.40M | 201.92M | 154.23M |
| Cash from Investing | 54.10M | 138.97M | 137.54M | 169.90M | 122.42M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.41M | 50.62M | 621.00K | 1.30M | 1.40M |
| Repurchase of Common Stock | -1.00K | 0.00 | 0.00 | 0.00 | -76.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 1.00K | -- |
| Cash from Financing | 50.41M | 50.62M | 621.00K | 1.30M | 1.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.52M | 24.57M | -33.32M | -3.92M | -38.64M |